Body mass index and blood glucose in psychiatric and general practice populations

about

Body mass index and blood glucose in psychiatric and general practice populations

Item

http://www.wikidata.org/entity/Q36953215

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Body mass index and blood glucose in psychiatric and general practice populations

@en

type

Item

label

Body mass index and blood glucose in psychiatric and general practice populations

@en

prefLabel

Body mass index and blood glucose in psychiatric and general practice populations

@en

P1476

Body mass index and blood glucose in psychiatric and general practice populations

@en

P2093

Christine Jefferies

http://www.w3.org/2001/XMLSchema#string

Jackie Kelly

http://www.w3.org/2001/XMLSchema#string

Kirsteen Miller

http://www.w3.org/2001/XMLSchema#string

Laura Chiwanda

http://www.w3.org/2001/XMLSchema#string

Matthew Cordiner

http://www.w3.org/2001/XMLSchema#string

Polash Shajahan

http://www.w3.org/2001/XMLSchema#string

Sarah McAvoy

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data

Physical health indicators in major mental illness: analysis of QOF data across UK general practice.

Schizophrenia and diabetes: epidemiological data.

Impact of socioeconomic deprivation on rate and cause of death in severe mental illness.

Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender.

Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.

Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.

"First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects.

P304

127-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1192/PB.BP.115.051219

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27280032

http://www.w3.org/2001/XMLSchema#string

P932

4887729

http://www.w3.org/2001/XMLSchema#string